Skip to main content

Advertisement

SpringerLink
Log in

Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Traditional Chinese herbal therapies are widely used for the treatment of chronic hepatitis C (CHC) in China and several Asian countries. The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) comparing peginterferon therapy with peginterferon plus Chinese herbal therapy for the treatment of CHC. The Cochrane Central Register of Controlled Trials, Medline, Science Citation Index, EMBASE, China National Knowledge Infrastructure, Wanfang Database, and China Biomedical Database were searched to identify RCTs that evaluated the virological response of CHC patients to peginterferon therapy and peginterferon plus Chinese herbal therapy. We statistically combined data using a fixed-effects meta-analysis according to the intention-to-treat principle. The literature search yielded 905 studies and nine RCTs composed of 858 patients matched the selection criteria. Overall, sustained virological response (SVR) was significantly higher in patients treated with peginterferon plus Chinese herbs than in patients treated with peginterferon alone (81 % vs. 64 %, respectively; odds ratio, 2.60; 95 % confidence interval: 1.32–5.14; p < 0.05). A combined therapy of peginterferon plus Chinese herbs was also superior to peginterferon therapy in achieving an early viral response (EVR, 80 % vs. 70 %, respectively), a viral response at week 24 of treatment (82 % vs. 73 %, respectively), and end-of-treatment viral response (ETVR, 73 % vs. 62 %, respectively). The combined therapy resulted in fewer relapses, fewer adverse events, and more rapid alanine transaminase normalization; however, both treatments yielded a similar rapid viral response (RVR, 53 % vs. 57 %, respectively). The current evidence suggests that combined therapy of peginterferon plus Chinese herbs yields a higher viral response and results in fewer relapses and fewer adverse events than peginterferon therapy alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Khuroo MS, Khuroo MS, Dahab ST (2004) Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 20:931–938

    Article  CAS  PubMed  Google Scholar 

  2. Hoofnagle JH (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26(3 Suppl 1):15S–20S

    Article  CAS  PubMed  Google Scholar 

  3. Anonymous (1999) EASL International Consensus Conference on Hepatitis C. Paris, 26–28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 30:956–961

    Article  Google Scholar 

  4. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345:41–52

    Article  CAS  PubMed  Google Scholar 

  5. Chinese Society of Hepatology and Chinese Society of Lemology and Parasitology (2004) Guideline for prevention and treatment of hepatitis C in China. Zhonghua Yi Xue Za Zhi 84:775–780

    Google Scholar 

  6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965

    Article  CAS  PubMed  Google Scholar 

  7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982

    Article  CAS  PubMed  Google Scholar 

  8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355

    Article  CAS  PubMed  Google Scholar 

  9. Zhao S, Liu E, Wei K, Wang Y, Li Y, Huang B, Chen Y, Yang P (2011) Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C. Eur J Clin Microbiol Infect Dis 30:51–57

    Article  CAS  PubMed  Google Scholar 

  10. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136:288–292

    Article  CAS  PubMed  Google Scholar 

  11. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132:296–305

    Article  CAS  PubMed  Google Scholar 

  12. Zhao S, Liu E, Wei K, Lu S, Chu Y, Li Y, Wang Y, Huang B, Chen Y, Yang P (2011) Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: a meta-analysis of randomised trials. Antiviral Res 89:156–164

    Article  CAS  PubMed  Google Scholar 

  13. Saydah SH, Eberhardt MS (2006) Use of complementary and alternative medicine among adults with chronic diseases: United States 2002. J Altern Complement Med 12:805–812

    Article  PubMed  Google Scholar 

  14. Fu M, Gu X, Zhu Y (2013) Combination of Chinese traditional and western medicine in treating 32 patients with chronic hepatitis C (In Chinese). Chin J Integr Tradit West Med Liver Dis 23:4–6

    Google Scholar 

  15. Ji X, Gu X, Fu M (2012) Combination of Chinese traditional and western medicine in treating patients with chronic hepatitis C (In Chinese). Jiangsu J Tradit Chin 44:30–31

    Google Scholar 

  16. Jing X, Qi P, Zhang Y, Dong J, Li Y, Dong X, Pei Q (2010) Clinical observation of combined Chinese medicine and pegylated interferon α-2 a in treating chronic hepatitis C (In Chinese). Shanghai J Tradit Chin Med 44:36–38

    Google Scholar 

  17. Nie H, Chen J, Wang C, Ling Q, Wang R, Chen Y, Dong H (2012) A prospective study on Fuzhengjiedu prescription combined with standard treatment program for patients with genotype 1 chronic hepatitis C (In Chinese). Infect Dis Inf 25:170–173

    Google Scholar 

  18. Qiu R, Wang X, He X, Ye X, Lin G, Huang Q, Hu Z, Huang X (2012) Clinical study on treating chronic hepatitis C with the cogongrass rhizome decoction combined with interferon and ribavirin (In Chinese). Clin J Chin Med 4:5–8

    Google Scholar 

  19. Sun Y (2005) Anti-HCV particles combined with pegylated interferon plus ribavirin in the treatment of chronic hepatitis curative effect observation (in Chinese). Unpublished master’s thesis, Shandong University of Traditional Chinese Medicine, Jinan, China

  20. Wang X, Yang A, Zeng F, Yu J (2012) Combination of Chinese traditional and western medicine in treating patients with chronic hepatitis C (in Chinese). J Guangxi Univ Chin Med 15:7–9

    Google Scholar 

  21. Xie M, Gao O, Tan X (2013) Clinical study of treatment of 84 chronic hepatitis C patients with Peginterferon, Ribavirin and Jiedushengbai Granula (in Chinese). China Mod Med 20:124–126

    Google Scholar 

  22. Zhang F (2009) Traditional Chinese medicine and western medicine combined therapy for 30 cases of chronic hepatitis C (in Chinese). Tradit Chin Med Res 22:27–28

    Google Scholar 

  23. Iafolla M (2002) Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C. Sidahora 4:8–10

    PubMed  Google Scholar 

  24. Guideline on Hepatitis C - European Medicines Agency. Available online at: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003461

  25. Wang BE (2000) Management of chronic hepatitis B: treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol 15(Suppl):E67–E70

    Article  CAS  PubMed  Google Scholar 

  26. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S (2011) Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 55:69–75

    Article  PubMed  Google Scholar 

  27. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC (2007) Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22:832–836

    Article  CAS  PubMed  Google Scholar 

  28. Zhao SH, Chu YL, Cheng DX, Waqar AB, Yu Q, Yang PH, Xue X, Yang HJ, Liu EQ (2009) Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C. Int J Clin Pract 63:1334–1339

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was partly supported by the Fundamental Research Funds for the Central Universities, the China Postdoctoral Science Foundation (201104669), the National Natural Science Foundation of China (81070250 and 81270348), the National Science and Technology Support Program (2012BAI39B02), and a Public Service Platform Grant and Science Foundation of Shaanxi Province (2010FWPT-15, 2012FWPT-03, 2012KJXX-07).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Key Laboratory of Environment and Genes Related to Diseases of the Education Ministry, Xi’an Jiaotong University School of Medicine, Shaanxi, China

    D. Cheng, E. Liu, M. Wu, G. Cheng & S. Zhao

  2. Laboratory for Lipid Metabolism and Atherosclerosis, Xi’an Jiaotong University Cardiovascular Research Center, Shaanxi, 710061, China

    D. Cheng, E. Liu, Y. Li, R. Liu, L. Bai, Y. Chen, Y. Wang & S. Zhao

  3. The Third Affiliated Hospital of the School of Medicine, Xi’an Jiaotong University, Shaanxi, China

    D. Cheng, M. Wu & G. Cheng

  4. Institute of Molecular Virology, Xi’an Jiaotong University School of Medicine, Shaanxi, China

    Y. Chu

Authors
  1. D. Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G. Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Zhao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheng, D., Liu, E., Li, Y. et al. Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis 33, 433–438 (2014). https://doi.org/10.1007/s10096-013-1973-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-013-1973-y

Keywords

Search

Navigation